BiotechTube

BDB001

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumor, Solid

Conditions

Tumor, Solid

Trial Timeline

Aug 30, 2021 → May 1, 2023

NCT ID
NCT04819373

About BDB001

BDB001 is a phase 2 stage product being developed by Eikon Therapeutics for Tumor, Solid. The current trial status is completed. This product is registered under clinical trial identifier NCT04819373. Target conditions include Tumor, Solid.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04819373Phase 2Completed

Competing Products

20 competing products in Tumor, Solid

See all competitors
ProductCompanyStageHype Score
E7050EisaiPhase 1
33
FruquintinibHUTCHMEDPhase 1
28
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
30
CixutumumabEli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
25
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
25
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
25
ZN-c3 + Bevacizumab + PembrolizumabZentalis PharmaceuticalsPhase 1
25
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
25
AzenosertibZentalis PharmaceuticalsPhase 1
25
IMC-18F1Eli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
ACR-2316Acrivon TherapeuticsPhase 1
25

Other Products from Eikon Therapeutics

EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + CarboplatinPhase 2
47
EIK1004-001 (IMP1707-001)Phase 1/2
36
IMP1734Phase 1/2
36
BDB001 (EIK1001) + AtezolizumabPhase 1
28